Sign in Sign up for free

Last updated: 3 October 2023 at 5:03pm EST

Amos Bar-Shalev Net Worth




The estimated Net Worth of Amos Bar Shalev is at least $1.75 Thousand dollars as of 2 December 2009. Mr. Shalev owns over 1,680 units of Protalix BioTherapeutics stock worth over $1,747 and over the last 15 years he sold PLX stock worth over $0. In addition, he makes $0 as Independent Director at Protalix BioTherapeutics.

Mr. Shalev PLX stock SEC Form 4 insiders trading

Amos has made over 1 trades of the Protalix BioTherapeutics stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 1,680 units of PLX stock worth $14,263 on 2 December 2009.

The largest trade he's ever made was buying 1,680 units of Protalix BioTherapeutics stock on 2 December 2009 worth over $14,263. On average, Amos trades about 420 units every 0 days since 2009. As of 2 December 2009 he still owns at least 1,680 units of Protalix BioTherapeutics stock.

You can see the complete history of Mr. Shalev stock trades at the bottom of the page.





Amos Bar-Shalev biography

Amos Bar-Shalev is the Independent Director of Protalix BioTherapeutics Inc., has served as our director since July 2008. Previously, Mr. Bar Shalev served as a director of Protalix Ltd. from 2005 through January 2008, and as our director from 2006 through 2008. Mr. Bar Shalev brings to us extensive experience in managing technology companies. Currently, Mr. Bar Shalev serves on the boards of directors of Aposense Ltd. (TASE: APOS), an Israeli publicly-traded company listed on the TASE, since 2011, as well as Twine Solutions Ltd., a privately-held technology company, since 2015, and of Steam CC Ltd., since 2017, both privately-held Israeli companies. From 2004 through 2012, Mr. Bar Shalev served as a director of Technorov Holdings (1993) Ltd. and managed its portfolio. In addition, he served on the board of directors of Highcon Systems Ltd., a privately-held Israeli company, from 2010 through 2012. From 1997 through 2004, he was a Managing Director of TDA Capital Partners, a management company of the TGF (Templeton Tadiran) Fund. From 2004 through 2007, he was the President of Win Buyer Ltd. He has served on the board of directors of a number of Israeli publicly traded and privately-held Israeli companies including, among others, Velox Ltd., NESS Ltd. (acquired by BioNess Inc.), Idanit (acquired by Scitex Corporation Ltd.), Objet Geometrix (merged with Stratasys, Inc. (NASDAQ:SSYS)), Verisity, Scitex Vision (acquired by Hewlett Packard), Golden Wings Investment Company Ltd., the venture capital fund of the Israeli Air Force Veterans Business Club, Win Buyer Ltd. and Sun Light Ltd. He received his B.Sc. in Electrical Engineering from the Technion, Israel in 1978 and M.B.A. from the Tel Aviv University in 1981. He holds the highest award from the Israeli Air Force for technological achievements.



How old is Amos Shalev?

Amos Shalev is 66, he's been the Independent Director of Protalix BioTherapeutics since 2008. There are 4 older and 9 younger executives at Protalix BioTherapeutics. The oldest executive at Protalix BioTherapeutics Inc. is Aharon Schwartz, 75, who is the Independent Director.

What's Amos Shalev's mailing address?

Amos's mailing address filed with the SEC is C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, L3, 2161401.

Insiders trading at Protalix BioTherapeutics

Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber, and Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.



What does Protalix BioTherapeutics do?

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase



What does Protalix BioTherapeutics's logo look like?

Protalix BioTherapeutics Inc. logo

Complete history of Mr. Shalev stock trades at Protalix BioTherapeutics

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
2 Dec 2009 PLX Protalix BioTherapeutics Inc. Amos Bar Shalev
Buy 1,680 $8.49 $14,263
2 Dec 2009
1,680 ↗


Protalix BioTherapeutics executives and stock owners

Protalix BioTherapeutics executives and other stock owners filed with the SEC include: